This Oxfordshire firm, led by Eliot Forster, 50, develops drugs that harness the body’s immune system to fight cancer. Last year it completed the largest private financing for a life sciences company in Europe, raising £205m from investors including Woodford Investment Management and Malin. It also set up an American office. The company’s partnerships with large pharmaceutical firms such as Glaxo Smith Kline and Astra Zeneca brought revenue of £14.3m in 2015, when it also made a large loss.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.